• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Article

Illinois firm develops soy-based molecule with sunscreen properties

Cary, Ill. - Biotech firm iSoy Technologies, based here, has developed a molecule with sunscreen properties known as FSG33 - the result of joining a compound found in the soy plant with ferulic acid.

Cary, Ill. - Biotech firm iSoy Technologies, based here, has developed a molecule with sunscreen properties known as FSG33 - the result of joining a compound found in the soy plant with ferulic acid.

The company is launching a class of natural bio-lipids that may offer the benefits of active ingredients previously deemed unsuitable for use in sunscreens and cosmetic formulations, reports Cosmeticsdesign.com.

The ferulic soy glyceride (FSG) is produced through an enzyme reaction that produces no toxic by-products, unlike synthetic chemical reactions, according to the company, which will use the same technology to create other bio-lipid molecules.

When applied to the surface of the skin, the bio-lipid molecules act as a reservoir for essential nutrients from which depleted skin can replenish itself, according to an iSoy statement. The FSG molecules appear to improve the solubility, stability and delivery of other skincare actives, which will help to transport nutrients to the skin.

According to an iSoy statement, the company expects to market this particular attribute of FSG in formulations and is exploring the potential of other bio-lipids, with a goal of creating at least 25 new molecules based on the same technology.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

© 2025 MJH Life Sciences

All rights reserved.